![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Bernstein Clinical Research Center |
---|---|
Information provided by: | Bernstein Clinical Research Center |
ClinicalTrials.gov Identifier: | NCT00242359 |
Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.
Condition | Intervention | Phase |
---|---|---|
Allergy Induced Asthma |
Drug: omalizumab |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Bernstein Clinical Research Cente ( Jonathan A. Bernstein, MD ) |
Study ID Numbers: | 2085 |
Study First Received: | October 17, 2005 |
Last Updated: | January 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00242359 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Lung Diseases, Obstructive Hypersensitivity Respiratory Tract Diseases Bronchial Diseases Lung Diseases Hypersensitivity, Immediate |
Anti-Asthmatic Agents Asthma Anti-Allergic Agents Omalizumab Respiratory Hypersensitivity |
Respiratory System Agents Bronchial Diseases Immune System Diseases Anti-Asthmatic Agents Asthma Anti-Allergic Agents Pharmacologic Actions Lung Diseases, Obstructive |
Hypersensitivity Respiratory Tract Diseases Lung Diseases Therapeutic Uses Hypersensitivity, Immediate Respiratory Hypersensitivity Omalizumab |